Home › Funds › Soleus Capital Management, L.P. › BBNX

Soleus Capital Management, L.P. position in BBNX

BETA BIONICS INC · Health Care

Soleus Capital Management, L.P. reported holding 4,393,714 shares of BBNX (BETA BIONICS INC) in its Q2 2026 13F filing — a position valued at US$68.8M, representing 2.37% of its reported portfolio and ranking #10 among its reported holdings. Soleus Capital Management, L.P. has disclosed BBNX holdings in 6 of the last 6 reported quarters, going back to Q1 2025.

Latest position (Q2 2026)4.39M sh
Reported value held$68.85M
Portfolio Weight2.37%
First reportedQ1 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Soleus Capital Management, L.P.'s BBNX position evolved

Soleus Capital Management, L.P. first disclosed a stake in BBNX in Q1 2025 at 3,395,341 shares (US$41.6M). The position peaked in Q4 2025 at 2,534,565 shares, worth US$77.2M. Across 6 filings, Soleus Capital Management, L.P. increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 4,393,714 shares valued at US$68.8M — an increase of 39,213 shares quarter over quarter.. Notable position changes include a 35% trim in Q4 2025 (shares fell 67% over the following quarter), a 72% increase in Q1 2026 (shares rose 56% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2025 3.40M $41.56M New
Q2 2025 3.82M $55.62M Add
Q3 2025 3.87M $76.90M Add
Q4 2025 2.53M $77.23M Reduce
Q1 2026 4.35M $43.63M Add
Q2 2026 4.39M $68.85M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBNX and 13F data

BBNX (BETA BIONICS INC) is a Health Care company. 52 other funds we track also report a position in BBNX — the largest reported positions include EVENTIDE ASSET MANAGEMENT, LLC (US$98.1M), Sands Capital Alternatives, LLC (US$58.1M), Vestal Point Capital, LP (US$25.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBNX

All BBNX fund holders →

FAQ

How long has Soleus Capital Management, L.P. held BBNX?

Soleus Capital Management, L.P. has disclosed BBNX holdings in 6 of the last 6 reported quarters, going back to Q1 2025.

What is Soleus Capital Management, L.P.'s current position in BBNX?

As of Q2 2026, Soleus Capital Management, L.P. holds 4.39M shares of BBNX (BETA BIONICS INC), valued at $68.85M, representing 2.37% of its reported portfolio and ranking #10.

Has Soleus Capital Management, L.P. been buying or selling BBNX?

In the latest 13F filing (Q2 2026), Soleus Capital Management, L.P. increased its position in BBNX. The position peaked in Q4 2025 at 2.53M shares.

Which other funds hold BBNX?

Other major institutional holders of BBNX include EVENTIDE ASSET MANAGEMENT, LLC, Sands Capital Alternatives, LLC, Vestal Point Capital, LP, among 52 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.